Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors

Xenobiotica

Volumn 42, Issue 2, 2012, Pages 139-156

  Brents, Lisa K ^b   Medina Bolivar, Fabricio ^a   Seely, Kathryn A ^b   Nair, Vipin ^a   Bratton, Stacie M ^b   Opo Olazabal, Luis ^a   Patel, Ronak Y ^c,d   Liu, Haining ^c   Doerksen, Robert J ^c   Prather, Paul L ^b   Radominska Pandya, Anna ^b  

^a ARKANSAS STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bioproduction; Cannabinoid receptors; G protein activity; Molecular modelling; Natural products; UDP glucuronosyltransferases

Indexed keywords

ARACHIDIN 1; ARACHIDIN 3; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; PICEATANNOL; RESVERATROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG GLUCURONIDATION; DRUG METABOLISM; LIVER MICROSOME; MOUSE; NONHUMAN;

ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL AVAILABILITY; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; GLUCURONOSYLTRANSFERASE; HEMITERPENES; HUMANS; KINETICS; MASS SPECTROMETRY; METABOLIC DETOXICATION, PHASE II; MODELS, MOLECULAR; PRENYLATION; RECEPTORS, CANNABINOID; RECOMBINANT PROTEINS; STILBENES;

ARACHIS HYPOGAEA;

EID: 84855451762     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.609570     Document Type: Article

References (62)

1. Abbott JA, Medina-Bolivar F, Martin EM, Engelberth AS, Villagarcia H, Clausen EC, Carrier DJ. (2010). Purification of resveratrol, arachidin-1, and arachidin-3 from hairy root cultures of peanut (Arachis hypogaea) and determination of their antioxidant activity and cytotoxicity. Biotechnol Prog 26:1344-1351.
2. Asensi M, Medina I, Ortega A, Carretero J, Baño MC, Obrador E, Estrela JM. (2002). Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 33:387-398. (Pubitemid 34786278)
3. Baur JA, Sinclair DA. (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493-506. (Pubitemid 44136961)
4. Bifulco M, Santoro A, Laezza C, Malfitano AM. (2009). Cannabinoid receptor CB1 antagonists state of the art and challenges. Vitam Horm 81:159-189.
5. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand JP, Le Fur G, Casellas P. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339. (Pubitemid 27382869)
6. Brill SS, Furimsky AM, Ho MN, Furniss MJ, Li Y, Green AG, Bradford WW, Green CE, Kapetanovic IM, Iyer LV. (2006). Glucuronidation of trans-resveratrol by human liver and intestinal microsomes and UGT isoforms. J Pharm Pharmacol 58:469-479.
7. Calamini B, Ratia K, Malkowski MG, Cuendet M, Pezzuto JM, Santarsiero BD, Mesecar AD. (2010). Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J 429:273-282.
8. Chang JC, Lai YH, Djoko B, Wu PL, Liu CD, Liu YW, Chiou RY. (2006). Biosynthesis enhancement and antioxidant and anti-inflammatory activities of peanut (Arachis hypogaea L.) arachidin-1, arachidin-3, and isopentadienylresveratrol. J Agric Food Chem 54:10281-10287. (Pubitemid 46159039)
9. Cheng Y, Prusoff WH. (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
10. Condori J, Medrano G, Sivakumar G, Nair V, Cramer C, Medina-Bolivar F. (2009). Functional characterization of a stilbene synthase gene using a transient expression system in planta. Plant Cell Rep 28:589-599.
11. Condori J, Sivakumar G, Hubstenberger J, Dolan MC, Sobolev VS, Medina-Bolivar F. (2010). Induced biosynthesis of resveratrol and the prenylated stilbenoids arachidin-1 and arachidin-3 in hairy root cultures of peanut: Effects of culture medium and growth stage. Plant Physiol Biochem 48:310-318.
12. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. (2010). Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54:7-16.
13. Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V, Della Ragione F. (2007). Resveratrol: From basic science to the clinic. Cell Cycle 6:2495-2510. (Pubitemid 350058668)
14. De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. (2000). Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica 30:857-866.
15. Deadwyler SA, Hampson RE, Bennett BA, Edwards TA, Mu J, Pacheco MA, Ward SJ, Childers SR. (1993). Cannabinoids modulate potassium current in cultured hippocampal neurons. Recept Channels 1:121-134.
16. Diaz P, Xu J, Astruc-Diaz F, Pan HM, Brown DL, Naguib M. (2008). Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain. J Med Chem 51:4932-4947.
17. Djoko B, Chiou RY, Shee JJ, Liu YW. (2007). Characterization of immunological activities of peanut stilbenoids, arachidin-1, piceatannol, and resveratrol on lipopolysaccharide-induced inflammation of RAW 264.7 macrophages. J Agric Food Chem 55:2376-2383. (Pubitemid 46556227)
18. Doerge DR, Chang HC, Churchwell MI, Holder CL. (2000). Analysis of soy isoflavone conjugation in vitro and in human blood using liquid chromatography-mass spectrometry. Drug Metab Dispos 28:298-307. (Pubitemid 30137054)
19. Fraga CG. (2007). Plant polyphenols: How to translate their in vitro antioxidant actions to in vivo conditions. IUBMB Life 59:308-315. (Pubitemid 46763776)
20. Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, Hohmann AG. (2007). Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: A comparative analysis. Br J Pharmacol 150:153-163. (Pubitemid 46160605)
21. Hampson AJ, Grimaldi M, Axelrod J, Wink D. (1998). Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95:8268-8273. (Pubitemid 28326102)
22. Han YS, Bastianetto S, Dumont Y, Quirion R. (2006). Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain. J Pharmacol Exp Ther 318:238-245.
23. Huang CP, Au LC, Chiou RY, Chung PC, Chen SY, Tang WC, Chang CL, Fang WH, Lin SB. (2010). Arachidin-1, a Peanut Stilbenoid, Induces Programmed Cell Death in Human Leukemia HL-60 Cells. J Agric Food Chem.
24. Humphrey W, Dalke A, Schulten K. (1996). VMD: Visual molecular dynamics. J Mol Graph 14:33-8, 27.
25. Joseph JA, Fisher DR, Cheng V, Rimando AM, Shukitt-Hale B. (2008). Cellular and behavioral effects of stilbene resveratrol analogues: Implications for reducing the deleterious effects of aging. J Agric Food Chem 56:10544-10551.
26. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. (2010). Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol.
27. Klein TW. (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5:400-411. (Pubitemid 40685989)
28. Kunos G, Osei-Hyiaman D, Bátkai S, Sharkey KA, Makriyannis A. (2009). Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci 30:1-7.
29. Kurkela M, García-Horsman JA, Luukkanen L, Mörsky S, Taskinen J, Baumann M, Kostiainen R, Hirvonen J, Finel M. (2003). Expression and characterization of recombinant human UDPglucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J Biol Chem 278:3536-3544. (Pubitemid 36801076)
30. Kuuranne T, Kurkela M, Thevis M, Schänzer W, Finel M, Kostiainen R. (2003). Glucuronidation of anabolic androgenic steroids by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 31:1117-1124. (Pubitemid 37048283)
31. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R, Makriyannis A. (1999). Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42:769-776. (Pubitemid 29110792)
32. Lançon A, Hanet N, Jannin B, Delmas D, Heydel JM, Lizard G, Chagnon MC, Artur Y, Latruffe N. (2007). Resveratrol in human hepatoma HepG2 cells: Metabolism and inducibility of detoxifying enzymes. Drug Metab Dispos 35:699-703. (Pubitemid 46641555)
33. Lee HK, Choi EB, Pak CS. (2009). The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Curr Top Med Chem 9:482-503.
34. Lekli I, Szabo G, Juhasz B, Das S, Das M, Varga E, Szendrei L, Gesztelyi R, Varadi J, Bak I, Das DK, Tosaki A. (2008). Protective mechanisms of resveratrol against ischemia-reperfusioninduced damage in hearts obtained from Zucker obese rats: The role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol 294:H859-H866. (Pubitemid 351253297)
35. Li YY, Li YN, Ni JB, Chen CJ, Lv S, Chai SY, Wu RH, Yüce B, Storr M. (2010). Involvement of cannabinoid-1 and cannabinoid-2 receptors in septic ileus. Neurogastroenterol Motil 22:350-e88.
36. Little JM, Kurkela M, Sonka J, Jäntti S, Ketola R, Bratton S, Finel M, Radominska-Pandya A. (2004). Glucuronidation of oxidized fatty acids and prostaglandins B1 and E2 by human hepatic and recombinant UDP- glucuronosyltransferases. J Lipid Res 45:1694-1703. (Pubitemid 39296209)
37. Mackie K, Hille B. (1992). Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 89:3825-3829.
38. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
39. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90.
40. Medina-Bolivar F, Condori J, Rimando AM, Hubstenberger J, Shelton K, O'Keefe SF, Bennett S, Dolan MC. (2007). Production and secretion of resveratrol in hairy root cultures of peanut. Phytochemistry 68:1992-2003. (Pubitemid 47030617)
41. Medina-Bolivar F, Dolan M, Bennett S, Condori J, Hubstenberger J; 2010. Production of stilbenes in plant hairy root cultures. patent U.S. Patent 7,666,677.
42. Miksits M, Maier-Salamon A, Vo TP, Sulyok M, Schuhmacher R, Szekeres T, Jäger W. (2010). Glucuronidation of piceatannol by human liver microsomes: Major role of UGT1A1, UGT1A8 and UGT1A10. J Pharm Pharmacol 62:47-54.
43. Munro S, Thomas KL, Abu-Shaar M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65. (Pubitemid 23305569)
44. Nie J, Lewis DL. (2001). Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration. J Neurosci 21:8758-8764. (Pubitemid 33054839)
45. Pavón FJ, Serrano A, Pérez-Valero V, Jagerovic N, Hernández-Folgado L, Bermúdez-Silva FJ, Macías M, Goya P, de Fonseca FR. (2008). Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: Effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol 20 Suppl 1:116-123. (Pubitemid 351552685)
46. Pertwee RG. (2005). Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324.
47. Pervaiz S, Holme AL. (2009). Resveratrol: Its biologic targets and functional activity. Antioxid Redox Signal 11:2851-2897.
48. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. (2004). UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25:1605-1612.
49. Reggio PH. (2010). Endocannabinoid binding to the cannabinoid receptors: What is known and what remains unknown. Curr Med Chem 17:1468-1486.
50. Sabolovic N, Humbert AC, Radominska-Pandya A, Magdalou J. (2006). Resveratrol is efficiently glucuronidated by UDPglucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells. Biopharm Drug Dispos 27:181-189. (Pubitemid 43797114)
51. Sali A, Blundell TL. (1993). Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815. (Pubitemid 24007801)
52. Shen T, Wang XN, Lou HX. (2009). Natural stilbenes: An overview. Nat Prod Rep 26:916-935.
53. Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL. (2005). The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J Pharmacol Exp Ther 314:868-875. (Pubitemid 41043873)
54. Sivakumar G, Medina-Bolivar F, Lay JO Jr, Dolan MC, Condori J, Grubbs SK, Wright SM, Baque MA, Lee EJ, Paek KY. (2011). Bioprocess and bioreactor: Next generation technology for production of potential plant-based antidiabetic and antioxidant molecules. Curr Med Chem 18:79-90.
55. Surh YJ, Kundu JK, Na HK, Lee JS. (2005). Redox-sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals. J Nutr 135:2993S-3001S. (Pubitemid 43156578)
56. Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi PP, Fogliano V, Marchelli R. (2005). Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 49:495-504. (Pubitemid 40780396)
57. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32:1377-1382. (Pubitemid 39564557)
58. Wang YJ, He F, Li XL. (2003). [The neuroprotection of resveratrol in the experimental cerebral ischemia]. Zhonghua Yi Xue Za Zhi 83:534-536.
59. Weiss JN. (1997). The Hill equation revisited: Uses and misuses. FASEB J 11:835-841. (Pubitemid 27371892)
60. Wenzel E, Somoza V. (2005). Metabolism and bioavailability of transresveratrol. Mol Nutr Food Res 49:472-481.
61. Wittwer E, Kern SE. (2006). Role of morphine's metabolites in analgesia: Concepts and controversies. AAPS J 8:E348-E352. (Pubitemid 43840593)
62. Yazaki K, Sasaki K, Tsurumaru Y. (2009). Prenylation of aromatic compounds, a key diversification of plant secondary metabolites. Phytochemistry 70:1739-1745.